2027 ICD-10-CM Diagnosis Code C83.390Primary central nervous system lymphoma

ICD-10-CM Codes›C00–D49›C81-C96›C83

ICD-10-CM C83.390
CMSSource: CMS FY 2027 ICD-10-CM dataset · Effective Oct 1, 2026 – Sep 30, 2027

C83.390 is a billable ICD-10-CM diagnosis code for primary central nervous system lymphoma. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 820 through 825, 840 through 842, 974 through 976. As a secondary diagnosis, it counts as a complication or comorbidity (CC) and moves an inpatient stay to a higher severity level within its MS-DRG family. It does not count, however, when the principal diagnosis is one of 15 closely related codes. Coders also document this condition as diffuse large B-cell lymphoma of central nervous system. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Non-Hodgkin lymphoma.

For Medicare Advantage risk adjustment, C83.390 maps to CMS-HCC Category 20 (Lung and Other Severe Cancers) under the V28 model, adding a risk factor of about 1.136 for a community, non-dual, aged beneficiary in payment year 2027.

Code Identity

ICD-10-CM Code
C83.390
Billable Status
Yes — Valid for Submission
Code Describes
Primary central nervous system lymphoma
Short Description
Primary central nervous system lymphoma
Same as the full description in the CMS dataset.
Parent Code
Diffuse large B-cell lymphoma, extranodal and solid organ sites

Code Classification

ChapterC00–D49Neoplasms
SectionC81-C96Malignant neoplasms of lymphoid, hematopoietic and related tissue
CategoryC83Non-follicular lymphoma
This CodeC83.390Primary central nervous system lymphoma

Medicare Risk Adjustment (HCC)Billing

C83.390 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2027.

CMS-HCC V28 Category (Payment Model)
HCC 20— Lung and Other Severe Cancers
Payment HCC · PY 2027 one of 233 ICD-10-CM codes in this category
Risk Adjustment Factor (RAF) Weight
+1.136
community, non-dual, aged · ranges 0.672–1.214 across segments
Hierarchy
Superseded by HCC 17, HCC 18, and HCC 19
a more severe related category takes the payment when both are reported
Prior Model (CMS-HCC V24)
HCC 10
V24 retired V28 pays 100% of MA risk scores since PY 2026
Other CMS Models
PACE (CMS-HCC V22): HCC 10 · ESRD (V21): HCC 10 · ESRD (V24): HCC 10
ESRD V21 weights: 0.136 dialysis, 0.451–0.668 functioning graft · ESRD V24 weights: 0.111 dialysis, 0.467–0.780 functioning graft
Part D (RxHCC)
RxHCC 21 — Lymphomas and Other Hematologic Cancers
also risk-adjusts in the Part D prescription drug model (V08)

Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Diffuse large B-cell lymphoma of central nervous system
  • Non-Hodgkin's lymphoma of central nervous system

Instructional NotesGuidance

Instructions from the official ICD-10-CM Tabular List that apply to C83.390: its own notes plus those printed at C83.3, C83, block C81-C96, and Chapter 2. A note printed at a category, block or chapter applies to every code under it.

Applicable To

Conditions this code is used for: synonyms of the title or, for "other specified" codes, the conditions assigned to it. The list is not exhaustive.

  • PCNSL of brain
  • PCNSL of meninges
  • PCNSL of spinal cord
  • PCNSL NOS

Excludes1

Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.

On C83.390 itself
  • Primary central nervous system lymphoma, Burkitt (C83.79)
  • Primary central nervous system lymphoma, lymphoblastic (C83.59)
  • Primary central nervous system lymphoma, other (C83.89)
  • Primary central nervous system lymphoma, peripheral T-cell (C84.49)
From C83.3 Diffuse large B-cell lymphoma applies to 12 codes
  • mediastinal (thymic) large B-cell lymphoma (C85.2-)
  • mature T/NK-cell lymphomas (C84.-)
From C83 Non-follicular lymphoma applies to 78 codes
  • personal history of non-Hodgkin lymphoma (Z85.72)

Excludes2

Not included here: the excluded condition is not part of this code, but a patient may have both, so both codes may be reported.

From Block C81-C96 Malignant neoplasms of lymphoid, hematopoietic and related tissue applies to 533 codes
  • Kaposi's sarcoma of lymph nodes (C46.3)
  • secondary and unspecified neoplasm of lymph nodes (C77.-)
  • secondary neoplasm of bone marrow (C79.52)
  • secondary neoplasm of spleen (C78.89)

Notes

General instructions on how these codes are used.

From Chapter 2 (C00-D49) Neoplasms applies to 1,730 codes
  • Functional activity
  • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
  • Morphology [Histology]
  • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
  • Primary malignant neoplasms overlapping site boundaries
  • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
  • Malignant neoplasm of ectopic tissue
  • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).

Source: CMS ICD-10-CM Tabular List. How to read instructional notes.

Referenced in Other NotesGuidance

Instructional notes printed at other codes that name C83.390, its category, or a range that includes it.

Excludes1 2

These codes carry an Excludes1 note naming C83.390: they are not reported together with it, unless the two conditions are unrelated.

  • C83.8 Other non-follicular lymphoma
    T-cell rich B-cell lymphoma (C83.3-) names C83.3-, which includes this code
  • C88.4 Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma]
    high malignant (diffuse large B-cell) lymphoma (C83.3-) names C83.3-, which includes this code

Index to Diseases and InjuriesGuidance

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR NEO058
Non-Hodgkin lymphoma
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Primary Central Nervous System Lymphoma

    a non-hodgkin or hodgkin lymphoma that arises from the brain or spinal cord as a primary lesion. there is no evidence of lymphoma outside the central nervous system at the time of diagnosis.
  • Lymphoma, Large B-Cell, Diffuse

    malignant lymphoma composed of large b lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. the pattern is predominantly diffuse. most of these lymphomas represent the malignant counterpart of b-lymphocytes at midstage in the process of differentiation.

Patient EducationClinical

Lymphoma

Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas.

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Code History & ChangesHistory

Replacement C83.390 replaces the following previously assigned code(s):

  • Z85.72 - Personal history of non-Hodgkin lymphomas
FY 2025AddedAdded to the ICD-10-CM code setEffective October 1, 2024.
FY 2026No changes
FY 2027CurrentCurrent code set, no changesEffective October 1, 2026 through September 30, 2027.

Questions About C83.390Overview

What is the ICD-10 code for primary central nervous system lymphoma?

The ICD-10-CM code for primary central nervous system lymphoma is C83.390 (sometimes written as C83390). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

Is C83.390 a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report primary central nervous system lymphoma on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

What MS-DRG does C83.390 group to?

When primary central nervous system lymphoma is the principal diagnosis on an inpatient stay, it groups to MS-DRG 820, 821, 822, 823, 824, 825, 840, 841, 842, 974, 975, 976, with relative weights from 0.7879 to 6.2454 depending on complications. Higher weights mean higher Medicare reimbursement.

Is C83.390 a CC or MCC?

CMS lists C83.390 as a CC (complication or comorbidity) for FY 2027. Reported as a secondary diagnosis, it moves the inpatient stay to a higher-weighted DRG within its severity family. It does not count when the principal diagnosis is one of the 15 closely related codes in its exclusion list.

Can C83.390 be reported with C83.79?

Not as a rule. The Excludes1 note on C83.390 lists "Primary central nervous system lymphoma, Burkitt (C83.79)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).

What HCC is C83.390?

C83.390 (primary central nervous system lymphoma) maps to CMS-HCC Category 20 (Lung and Other Severe Cancers), commonly written as HCC 20, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2027. It mapped to HCC 10 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. In the Part D prescription drug model it maps to RxHCC 21.

Does C83.390 risk-adjust for Medicare Advantage payment?

Yes. When documented and reported on a Medicare Advantage encounter, C83.390 adds a risk adjustment factor of about 1.136 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.672 to 1.214 depending on the payment segment). A more severe related category (HCC 17, HCC 18, and HCC 19) supersedes it when both are reported. See the full factor table on the HCC 20 category page.